Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 8/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766643 | 0.93 | POLB (0.56) | GLAMAPK1NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL6499707 | 0.87 | GAA (0.52) | GLAMAPK1NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL6500635 | 0.83 | EP300 (0.57) | GLAMAPK1NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL6493124 | 0.79 | KDR (0.53) | L3MBTL1GAA | |
| SCHEMBL5763717 | 0.78 | NPC1 (0.49) | MAPK1NPC1ALDH1A1KDM4EGAA | |
| SCHEMBL5146626 | 0.78 | GSK3B (0.49) | MAPK1NPC1ALDH1A1KDM4EGAA | |
| SCHEMBL6499469 | 0.77 | GLA (0.48) | GLAMAPK1NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL5767044 | 0.76 | NPC1 (0.50) | NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL5767729 | 0.75 | GSK3B (0.52) | NPC1ALDH1A1GSK3BCYP1A2CYP3A4 | |
| SCHEMBL31580824 | 0.75 | MAPK1 (0.51) | GLAMAPK1NPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908932-B2 | Cancer therapy | ICONIX PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | ENTELOS HOLDING CORP. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035618-A2 | MODULATORS OF PHOSPHOINOSITIDE 3-KINASE | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | PIK3R1, PIK3R3, PIK3R4 | GLA 3551/4885MAPK1 109/4885NPC1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.